# STERIS

> STERIS supplies the equipment, consumables, software and services that hospitals, medical device makers and pharmaceutical manufacturers use to prevent infection and control contamination. Its three businesses span hospital sterile processing, outsourced industrial sterilization and life sciences manufacturing support.

- **Founded:** 1985
- **Headquarters:** Dublin, Ireland
- **Founders:** Raymond Kralovic (Founder; microbiologist)
- **Products:** V-PRO maX 2, AMSCO steam sterilizers, SPM Workflow Solutions, Applied Sterilization Technologies, Instrument and endoscope repair
- **Notable:** First SYSTEM 1 shipped in 1988., Initial public offering in 1992 at $7 per share., Joined the S&P 500 in 2019.

## Products & services

- **V-PRO maX 2** — Vaporized hydrogen peroxide low-temperature sterilization for compatible, properly prepared medical devices; cycle and load restrictions apply.
- **AMSCO steam sterilizers** — Steam sterilization equipment for healthcare sterile processing.
- **SPM Workflow Solutions** — Surgical asset tracking, guided workflows, digital records and reporting for instrument processing.
- **Applied Sterilization Technologies** — Contract sterilization and testing using radiation, gas and other validated processing technologies.
- **Instrument and endoscope repair** — Repair and maintenance services for reusable procedural instruments and scopes.
- **Life Sciences contamination control** — Pharmaceutical detergents, disinfectants, washing systems, sterilizers and VHP biodecontamination equipment and services.
- **Endoscope reprocessing** — Automated reprocessors, accessories, drying and storage equipment, and workflow support.

## Achievements

- First SYSTEM 1 shipped in 1988.
- Initial public offering in 1992 at $7 per share.
- Joined the S&P 500 in 2019.
- Completed acquisition of Cantel Medical in June 2021.
- Fiscal 2026 continuing-operations revenue reached $5.9359 billion.

## Latest updates

- **2026-10** — Agreed to acquire Xodus Medical for $2.1 billion at closing, plus up to $150 million in earnout consideration; closing anticipated by December 31, 2026, subject to conditions.
- **2026-08** — Announced a planned $600 million formulated chemistries manufacturing and distribution campus in North Carolina, expected to create approximately 335 jobs.
- **2026-08** — Reported fiscal 2027 first-quarter revenue of approximately $1.5 billion, up 7% year over year.
- **2026-05** — Reported fiscal 2026 continuing-operations revenue of $5.9359 billion, up 8.7%.

## Links

- Website: https://www.steris.com
- LinkedIn: https://www.linkedin.com/company/steris-corporation/
- Twitter/X: https://twitter.com/STERIS
- YouTube: https://www.youtube.com/@STERISHealthcareUSA
- Instagram: https://www.instagram.com/steris.healthcare.usa/
- Facebook: https://www.facebook.com/steriscorporate

---

Profile page: https://yespress.io/steris
Published by YesPress — https://yespress.io
Last updated: 2026-10-22